Keywords: Endocrine, Diabetes
Motivation: GLP-1 receptor agonists have shown favorable effects in improving obesity and ectopic fat deposition in type 2 diabetes patients. MRI-PDFF can serve as a tool for continuous, dynamic assessment of lipid content changes in patients.
Goal(s): Dynamic monitoring of fat content and lipid deposition changes in type 2 diabetes obese patients receiving glucagon-like peptide-1 receptor agonist treatment using MRI-PDFF.
Approach: 21 male diabetic patients received 3-month treatment: semaglutide (n=12) or loxenatide (n=9). Clinical data collected, pre/post 3.0T MRI scans (T1WI, T2WI, MRI-PDFF) measured fat.
Results: The semaglutide group showed significant fat reduction in multiple organs, while the loxenatide group reduced pancreatic fat fraction.
Impact: Semaglutide effectively controls blood glucose and body weight in type 2 diabetes obese patients. It also significantly reduces SAT and VAT while alleviating ectopic fat deposition. MRI-PDFF represents a non-invasive tool for continuous assessment of lipid content changes following treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords